Presenting features
| . | Median (range) . | No. of patients (%) . |
|---|---|---|
| Age, median, y | 65 (46-88) | |
| Sex, male-female ratio | 1.7:1 | |
| IgM paraprotein, g/L | 8 (IF-60) | 103 (100) |
| Monoclonal light chain type | ||
| κ | 48 (46) | |
| λ | 55 (54) | |
| Hemoglobin, g/L | 12.3 (8.2-17.7) | |
| Total white cell count, × 109/L | 7.0 (0.5-23.4) | |
| Platelets, × 109/L | 287 (18-757) | |
| Creatinine, μM | 103 (49-ESRD) | |
| Albumin, g/L | 35 (14-52) | |
| Bilirubin, mM | 9 (4-225) | |
| Alkaline phosphatase, IU/L | 103 (52-3488) | |
| 24-hour proteinuria, g/24 h | 1.0 (< 0.1-21) | |
| Creatinine clearance, mL/min | 56 (ESRD-152) | |
| ECOG performance status | ||
| 1 or less | 26 (25) | |
| 2 | 50 (49) | |
| 3 or more | 27 (26) | |
| Organ involvement | ||
| Liver, consensus criteria | 15 (14) | |
| Liver, SAP scintigraphy | 39 (38) | |
| Renal, consensus criteria | 55 (53) | |
| Renal, SAP scintigraphy | 49 (47) | |
| Cardiac, any involvement | 36 (35) | |
| Cardiac, IVS 15 mm or more | 4 (3) | |
| Lymph nodes | 22 (21) | |
| Peripheral neuropathy | 4 (3) | |
| Autonomic neuropathy | 8 (7) | |
| Soft tissue | 14 (13) | |
| Gastrointestinal tract | 5 (4) | |
| Respiratory | 4 (3) | |
| Total no. of organs, international consensus criteria | ||
| 1 organ | 47 (46) | |
| 2 organs | 35 (34) | |
| 3 or more organs | 21 (20) | |
| Total no. of organs, SAP scintigraphy | ||
| 1 organ | 6 (5) | |
| 2 organs | 61 (60) | |
| 3 or more organs | 36 (35) |
| . | Median (range) . | No. of patients (%) . |
|---|---|---|
| Age, median, y | 65 (46-88) | |
| Sex, male-female ratio | 1.7:1 | |
| IgM paraprotein, g/L | 8 (IF-60) | 103 (100) |
| Monoclonal light chain type | ||
| κ | 48 (46) | |
| λ | 55 (54) | |
| Hemoglobin, g/L | 12.3 (8.2-17.7) | |
| Total white cell count, × 109/L | 7.0 (0.5-23.4) | |
| Platelets, × 109/L | 287 (18-757) | |
| Creatinine, μM | 103 (49-ESRD) | |
| Albumin, g/L | 35 (14-52) | |
| Bilirubin, mM | 9 (4-225) | |
| Alkaline phosphatase, IU/L | 103 (52-3488) | |
| 24-hour proteinuria, g/24 h | 1.0 (< 0.1-21) | |
| Creatinine clearance, mL/min | 56 (ESRD-152) | |
| ECOG performance status | ||
| 1 or less | 26 (25) | |
| 2 | 50 (49) | |
| 3 or more | 27 (26) | |
| Organ involvement | ||
| Liver, consensus criteria | 15 (14) | |
| Liver, SAP scintigraphy | 39 (38) | |
| Renal, consensus criteria | 55 (53) | |
| Renal, SAP scintigraphy | 49 (47) | |
| Cardiac, any involvement | 36 (35) | |
| Cardiac, IVS 15 mm or more | 4 (3) | |
| Lymph nodes | 22 (21) | |
| Peripheral neuropathy | 4 (3) | |
| Autonomic neuropathy | 8 (7) | |
| Soft tissue | 14 (13) | |
| Gastrointestinal tract | 5 (4) | |
| Respiratory | 4 (3) | |
| Total no. of organs, international consensus criteria | ||
| 1 organ | 47 (46) | |
| 2 organs | 35 (34) | |
| 3 or more organs | 21 (20) | |
| Total no. of organs, SAP scintigraphy | ||
| 1 organ | 6 (5) | |
| 2 organs | 61 (60) | |
| 3 or more organs | 36 (35) |
IF indicates immunofixation positive only; and ESRD, end-stage renal failure.